ABSTRACT
Cogan's syndrome is a rare autoimmune inflammatory disease, characterized by interstitial keratitis and audio-vestibular signs. The syndrome was first described in 1945 by David G. Cogan. Then, it was only in 1980 when Haynes et al. proposed diagnostic criteria for patients with other symptoms and was qualified as atypical form of Cogan's syndrome. Herein, we report a case of a 28-year-old woman with atypical Cogan's syndrome. The patient was treated with corticosteroids and received a cochlear implant.
Subject(s)
Apraxias/congenital , Autoimmune Diseases , Cochlear Implants , Cogan Syndrome , Keratitis , Female , Humans , Adult , Cogan Syndrome/complications , Cogan Syndrome/diagnosis , Keratitis/diagnosis , SyndromeSubject(s)
Precursor Cell Lymphoblastic Leukemia-Lymphoma , Retinal Artery Occlusion , Retinal Artery , Retinal Vein Occlusion , Fluorescein Angiography , Humans , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis , Retinal Artery Occlusion/diagnosis , Retinal Artery Occlusion/etiology , Retinal Vein Occlusion/diagnosis , Retinal Vein Occlusion/etiologyABSTRACT
A new series of alkylating agents, 2-chloroethylnitrososulfamides (CENS), were developed on the model of 2-chloroethylnitrosoureas. Starting from chlorosulfonyl isocyanate, a four-step synthesis (carbamoylation-sulfamoylation, Mitsunobu alkylation, deprotection, and nitrosation) gives the title compounds in a 47-58% overall yield. The selection of the nitrosation site can be directed through an alternative route. The pharmacological evaluation shows a significant oncostatic activity towards both A549 and MCF7 cell lines.